Work

Height-Adjusted Bone Mineral Density and Growth in Children with Mucopolysaccharidosis: A Single-Center Retrospective Cohort with Preserved Endocrine Axes

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Objective. Skeletal involvement in the mucopolysaccharidoses (MPS) is well characterized, but two questions remain open: how to read bone mineral density (BMD) independently of skeletal dysplasia, and whether the endocrine axes are affected. We described growth, standard and height-adjusted BMD, and endocrine parameters in a pediatric MPS cohort from a region where consanguinity is common. Methods. We reviewed the records of 42 patients younger than 18 years followed at a single center between January 2020 and December 2023, reporting according to STROBE. Anthropometry was converted to age- and sex-specific z-scores. Areal BMD from lumbar DEXA was adjusted for height-for-age z-score using the Zemel method. Annual growth velocity was calculated only for patients with a follow-up interval of at least nine months. Puberty was staged clinically by Tanner criteria. Calcium metabolism, 25(OH)D, and the thyroid, adrenal and gonadal axes were assessed. Analyses were exploratory, and no correction for multiple comparisons was applied. Results. Girls made up 52.4% of the cohort; median age was 7.3 years (1.7–17.0) and median age at diagnosis 2.5 years, and 88.1% were receiving enzyme replacement therapy (ERT). Mean baseline height SDS was − 2.76 ± 2.54, and 61.9% met the criterion for short stature. Height SDS fell over follow-up (median change − 1.01 SDS; Wilcoxon p < 0.001). Among the 34 patients with both measurements, low BMD by standard DEXA dropped from 64.7% to 20.6% after height adjustment. Parathyroid hormone (PTH) tended to be higher in short-statured patients (median 50.0 vs 38.0 pg/mL; p = 0.054), whereas vitamin D overlapped between the two groups (17.9 vs 18.2 ng/mL; p = 0.805). In patients with adequate follow-up, annual growth velocity correlated strongly with chronological age (rho = − 0.61) and with baseline height SDS (rho = 0.59; both p < 0.001). Thyroid, adrenal and gonadal parameters showed no clinically meaningful deviation. Conclusion. In subtypes with marked skeletal dysplasia, standard DEXA systematically underestimates BMD; bone assessment in MPS should rest on the height-adjusted score. The tendency for PTH to rise independently of vitamin D in short stature is a hypothesis-level finding that needs confirmation. The broadly preserved endocrine axes point to the skeletal–growth axis as the primary problem in MPS.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W7235534066
Cites: 22
Cited by:
Related to: 10